Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.
about
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumorIdentification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejectionIdentification of a meiosis-specific protein as a member of the class of cancer/testis antigensA new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomasTransfer of efficient anti-melanocyte T cells from vitiligo donors to melanoma patients as a novel immunotherapeutical strategyNew perspectives on the role of vitiligo in immune responses to melanomaSelf-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapyMelanoma Peptide Vaccines.Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity.Generation and characterization of two human alpha/beta T cell clones. Recognizing autologous breast tumor cells through an HLA- and TCR/CD3-independent pathway.Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.Autoimmune melanocyte destruction in vitiligo.Vaccines in oncology: background and clinical potential.Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptideT-cell antigens in cancerHuman CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene.Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes.Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crestImmunology and immunotherapy approaches for prostate cancer.T-cell recognition of human melanoma antigensMolecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.Enhancing the recognition of tumour associated antigens.Vitiligo, reactive oxygen species and T-cells.T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients.Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.Interleukins 1alpha and 1beta secreted by some melanoma cell lines strongly reduce expression of MITF-M and melanocyte differentiation antigens.Biological therapy: approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic targetDevelopment of cancer vaccine by tumor rejection antigens.Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy.Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.Genes coding for melanoma antigens recognised by cytolytic T lymphocytes.T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clonImmunotherapy of Human Melanoma With Gene-Modified Tumor Cell Vaccines.Metastatic Melanoma of Uncertain Primary with 5-Year Durable Response after Conventional Therapy: A Case Report with Literature Review.
P2860
Q54897754-78BDBF90-A49D-4BD4-8C53-876BE4396FC6Q54897757-96DB2616-3D77-4DDA-A277-C0E9DBC0614BQ54897758-8598936A-DE0C-4489-9E6F-E2733375443FQ54897760-D52B8DFD-E4EA-4F3E-B7B8-77641ABA4E06Q54897764-2E4DE998-421C-4A7E-B601-4540BC77B121Q54897766-D99AAF1B-2728-445B-9D93-A0261A0A1F77Q54897773-CA17FD42-102E-4C70-9B2D-0CD16E426153Q54897784-E9C664CB-24B4-4548-BC36-9C7FD04E9E0DQ54897801-26DDB14C-01D1-41DC-AB92-4AE6796C47E6Q54897809-849F5D70-6FCE-41B5-8ABF-A910B4CA7343Q54902337-5B545DBC-B9D1-46A0-9BAE-75FDFC1FD638Q54902339-D21A7288-555D-47D9-A131-42619E959449Q54902341-D93608A7-1616-4724-A161-6438F97DED0CQ54902343-59982193-C256-48F2-B7D9-AD1EBDADB794Q54902344-97404F3A-E409-40E4-B331-0C1AF166CF05Q54904915-F47828FB-7803-466B-A984-D2A1F016946EQ54904917-B05E5717-3803-48CE-B9AC-5EF9BA8BBEF8Q54904933-AE3D12FA-8C59-4643-AA5A-C169AF8F220CQ54904936-9848E74B-D554-4930-A996-24B0B71A89F2Q54904959-735793B0-3644-4398-83DE-8826EE6A7871Q54904973-E4D38DAA-51F1-4B13-9889-0C1993300A20Q54904976-97C00148-69AB-4C6F-8358-A8D78DC70F93Q54904991-0B47B6BE-B6FA-47C4-9A8E-AA60F2B216AF
P1343
Q24312048-5F6143E5-B7D9-4979-8F92-BF69D3D94F03Q24561706-2EC16B65-AB47-41EC-AAE3-A50A6F829181Q24569553-E165EF51-FECA-41A5-AB9A-E436F8E29B92Q24679739-CED5BB5B-6D9B-44AB-8B9F-BC14E02A2E80Q24814910-18EB0305-20BD-4DD0-B28B-DF92A95E624CQ26996799-64B4FCC4-D523-40B1-ACEB-0EAAD1AA1280Q30305530-E900F59A-3165-4A7B-A1B9-67AA75AC8425Q30305778-5FF2BB60-7D63-499C-8CA7-A62FD6E27FF4Q34035564-EFBBE704-ED66-4A1A-B87A-D2EE0EE825B8Q34188697-A2BCE089-B213-4019-885D-AA286693D737Q34247704-4BDC5E15-70F1-4594-8D07-486C8814FE3DQ34335855-5B2B915E-B2EB-4F42-9227-5F25C415F7B8Q34439914-11842E5D-15EE-4408-93B9-5805278316AFQ34765735-409B8377-2952-489A-B467-20F7D2323469Q35179337-70FD5E94-ECBE-4BC1-865D-467AAABFC44CQ35789284-7CE8CDFF-244E-45B1-95E0-8CF7AFA286AEQ35990356-06469113-0C7B-4D9F-B51F-53E45F25B683Q36297606-8D1FE6B1-536F-41A3-833F-55E7D8658D6EQ36363449-81FF45F9-3C62-4A17-B638-03785E6D0403Q36364266-DCB1C14D-39E7-41C5-88CB-0876AB66C267Q36470250-D6DDCD64-FE5B-4FE7-9592-DA5625DE1894Q36786512-AC42B9E8-1656-434F-8949-C8A67E09C7F8Q36914400-C808C9A4-A227-40D3-B2CE-83075F5C7225Q36914404-5B5B19BB-EF6C-46D3-8362-6F985DA341ABQ37360526-467E31A9-2040-494D-BD75-3DB285070CA3Q37383437-5697E041-C272-4AA2-951B-BA6E02E5FF20Q37391100-80465D82-C74F-4318-BB65-0CDC1D08C941Q37801388-94A9A496-8529-4E69-8AD5-3C4E0C04A0C7Q38101679-74B7E4F1-933A-4F40-B25B-AD9EF6B2FF88Q38471940-356FC67D-EEE2-4909-A797-6A4B5EB0F50BQ39748369-99B1EAF3-38E2-412D-88AB-8EA50E5909D9Q40865882-EB0F7BC6-4719-468B-AC63-8A2EC9E3A368Q41455927-14F1043B-DCF9-470A-86EB-A3192F0A7C36Q41455932-6F53FCB1-A7C8-43D3-AE32-339B9F5D2D0CQ41483867-DEA66129-876D-43AA-A9FC-3752DF7CBABCQ41625946-CF60EBF5-75E7-4792-AEE7-F4CF4CA46A92Q41760687-76F8B15F-60FD-4A7F-94FB-FF56DE1FA336Q45868793-BAB4A77D-4D20-451F-89BA-56A6485CFCDEQ55372822-868C0015-351A-4DCE-94BB-8D1DCE83FD7E
P2860
Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Melanoma cells and normal mela ...... clones from melanoma patients.
@en
Melanoma cells and normal mela ...... clones from melanoma patients.
@nl
type
label
Melanoma cells and normal mela ...... clones from melanoma patients.
@en
Melanoma cells and normal mela ...... clones from melanoma patients.
@nl
prefLabel
Melanoma cells and normal mela ...... clones from melanoma patients.
@en
Melanoma cells and normal mela ...... clones from melanoma patients.
@nl
P2093
P2860
P4510
P356
P1476
Melanoma cells and normal mela ...... clones from melanoma patients.
@en
P2093
Anichini A
Maccalli C
Mazzocchi A
Mortarini R
Parmiani G
Squarcina P
P2860
P304
P356
10.1084/JEM.177.4.989
P407
P4510
P577
1993-04-01T00:00:00Z